Partial
Partially Aligned
Patient Risk:
Low
Summary
The claims concern pricing, reimbursement, generic availability, and procurement, none of which are addressed in the supplied FDA-approved labeling. The claims do not directly contradict the label, but they are unsupported by it.
Category Scores
Accurate Statements
Unsupported Statements
Eltrombopag olamine pricing depends on the country.
Country-dependent pricing is not addressed in the supplied FDA-approved labeling.
Eltrombopag olamine pricing depends on the dose strength.
The relationship between pricing and dose strength is not addressed in the supplied FDA-approved labeling.
Eltrombopag olamine pricing depends on whether it is sold as a branded product or through a local supply or insurance channel.
Brand, supply-channel, and insurance-related pricing are not addressed in the supplied FDA-approved labeling.
A lower-cost version of eltrombopag olamine may be available in some countries as generic eltrombopag.
Generic availability and comparative cost are not addressed in the supplied FDA-approved labeling.
Pricing comparisons for eltrombopag olamine may depend on the availability of different formulations supplied under local procurement rules.
Formulation availability under local procurement rules and its effect on pricing are not addressed in the supplied FDA-approved labeling.
Country-specific sources such as national formularies, payer policies, and major pharmacy listings provide current eltrombopag olamine pricing and reimbursement information.
Pricing and reimbursement sources are not addressed in the supplied FDA-approved labeling.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claims do not address dosing, administration, efficacy, contraindications, warnings, or other safety-related matters. Their principal limitation is lack of support in the supplied labeling rather than a direct safety contradiction.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
All substantive claims are outside the scope of the supplied FDA-approved labeling and cannot be verified against it.
Suggested Improvement
Clearly identify the statements as non-label pricing information and avoid presenting them as information derived from the FDA-approved prescribing information.